Changes in Hong Kong stocks | Changfeng Pharmaceutical (02652) rose more than 10% intraday, core management voluntarily extended the ban on shares held for six months

The Zhitong Finance App learned that Changfeng Pharmaceutical (02652) rose more than 10% in the intraday period. As of press release, it rose 7.22% to HK$6.165, with a turnover of HK$585.869 million.

According to the news, Changfeng Pharmaceutical announced that it received Dr. Liang Wenqing, the company's co-founder, chairman, executive director and CEO, and Dr. Li Li, the company's co-founder, executive director and chief scientific officer, and the company's co-founder, executive director and chief scientific officer. The two promised to extend the ban on their shares for another 6 months after the original ban expires on October 7. The sales ban will be extended from October 8, 2026 to April 7, 2027.

It is worth noting that Changfeng Pharmaceutical's self-developed long-term inhalation powder candidate ICF001 has recently obtained multiple implied clinical trial licenses, achieving full coverage of the four major indications of PAH, PH-ILD, IPF, and PPF, making it the first domestic company to advance this type of long-acting inhalation prodrug to the clinical trial stage in China.